Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-28
2010-02-16
Angell, J. E (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500
Reexamination Certificate
active
07662796
ABSTRACT:
The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
REFERENCES:
patent: 2003/0225022 (2003-12-01), Taylor et al.
patent: WO 96/25492 (1996-08-01), None
patent: WO 99/01551 (1999-01-01), None
patent: WO 01/10906 (2001-02-01), None
patent: 03/010286 (2003-02-01), None
patent: 2004/078940 (2004-09-01), None
patent: 2004/113528 (2004-12-01), None
patent: 2005/007853 (2005-01-01), None
Jen et al. (Stem Cells 2000, vol. 18, p. 307-319).
Opalinska et al. (Nature Reviews Drug Discovery, 2002, vol. 1, p. 503-514).
Harborth et al. (2001) J. Cell Science 114:4557-4565.
Holen et al. (2002) Nucleic Acids Res. 30:1757-1766.
Boese et al., “Mechanical Insights Aid Computational Short Interfering RNA Design,” Methods in Enzymology 392:73-96, (2005).
Reynolds et al., “Rational siRNA design for RNA interference,” Nature Biotechnology 22:326-330, (2004).
Jin, Bao-Feng et al., “Proteomic analysis of ubiquitin-proteasome effects: insight into the future of eukaryotic initiation factor 5A,” Oncogene, Jul. 31, 2003, pp. 4819-4830, vol. 22, No. 31, Nature Publishing Group, XP-002388453, ISSN: 0950-9232.
Annexes to Form PCT/ISA/206, Invitation to Pay Additional Fees, Communication Relating to the Results of the Partial International Search, PCT/US2005/044266, Aug. 11, 2006, comprised of the Annex first, continuation and 4th of 5 extra sheets and the Patent Family Annex, European Patent Office, International Searching Authority, Rijswijk, NL.
Hayashizaki et al., “Analysis of the Mouse Transcriptome Based on Functional Annotation of 60,770 Full-Length cDNAs,” Nature, United Kingdom, vol. 420, No. 6915, pp. 563-573, ISSN: 0028-0836, XP002965277, Dec. 5, 2002.
Ruhl, M. et al., “Eukaryotic Initiation Factor 5A is a Cellular Target of the Human Immunodeficiency Virus Type 1 Rev Activation Domain Mediating Trans-Activation,” Journal of Cell Biology, Dec. 1, 1993, pp. 1309-1320, vol. 123, No. 6, XP000571505, ISSN: 0021-9525, Rockefeller University Press, New York, US.
Chen, K. Y. et al., “RNA Interference Analysis of the Function of Hypusine-Containing Eukaryotic Initiation Factor 5A in C. Elegans,” FASEB Journal (Federation of American Societies for Experimental Biology), Mar. 20, 2002, p. A162, vol. 16, No. 4, XP008033807, ISSN: 0892-6638, Bethesda, US.
Zhang, X. et al., “Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis,” Journal of Biological Chemistry, American Society of Biochemical Biologists, Mar. 12, 2003, pp. 10677-10684, vol. 279, No. 11, XP002343181, ISSN: 0021-9258, Birmingham, US.
International Search Report, PCT/US2005/025766, Mar. 17, 2006, comprised of Form PCT/ISA/220 and Form PCT/ISA/210, first & continuation sheets, second sheet: pp. 1-3, and patent family annex, European Patent Office, International Searching Authority, Rijswijk, NL.
Boone Adrienne
Cliche Dominic
Culp-Stewart Shelley
Flanagan John Gerard
Galton Bruce C.
Angell J. E
Senesco Technologies, Inc.
LandOfFree
Use of antisense oligonucleotides or siRNA to suppress... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of antisense oligonucleotides or siRNA to suppress..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of antisense oligonucleotides or siRNA to suppress... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165700